UK Markets open in 2 hrs 14 mins
  • NIKKEI 225

    -57.75 (-0.21%)

    +231.73 (+0.88%)

    -2.09 (-2.96%)

    -0.50 (-0.03%)
  • DOW

    +271.58 (+0.78%)

    +348.28 (+1.22%)
  • CMC Crypto 200

    +13.60 (+1.39%)
  • Nasdaq

    +114.58 (+0.78%)
  • ^FTAS

    +10.68 (+0.26%)

Original-Research: Cardiol Therapeutics (von GBC AG)

·2-min read
Original-Research: Cardiol Therapeutics - von GBC AG Einstufung von GBC AG zu Cardiol Therapeutics Unternehmen: Cardiol Therapeutics ISIN: CA14161Y2006 Anlass der Studie: Initial Coverage Report Empfehlung: BUY seit: 23.06.2021 Kursziel: 15,77 CAD Kursziel auf Sicht von: 31.12.2021 Letzte Ratingänderung: - Analyst: Julien Desrosiers; Felix Haugg One Product in two formulations, heart disease treatments in the making Cardiol Therapeutics provides leadership in therapeutic trials using Cannabidiol to take advantage of major opportunities in inflammatory heart disease. The company has an exclusive manufacturing agreement for a Cannabidiol pharmaceutical formulation which is highly concentrated and THC free (<10 ppm). There is a considerable quantity of scientific evidence showing that using Cannabidiol can be beneficial as an anti-inflammatory agent. The management has a proven track record of strong leadership coupled with substantial industry knowledge and competence in commercializing proprietary medications. The team enrolled their first patients in LANCER, a Phase II/III Outcomes Trial in High-risk Patients Hospitalized with COVID-19 in April 2021. The phase I Single and Multiple Ascending Dose Clinical Trial showed successful Topline results for CardiolRx(TM) in April 2021. The company applied for uplisting on the NASDAQ in March 2021. Cardiol Therapeutics has one product on the market in Canada, Cortalex(TM) CBD, exclusively available online at Medical Cannabis by Shoppers Inc. The company raised over 50M CAD during the past 12 months, with just over 53M total shares outstanding allowing for maximum future value creation for shareholders. Our estimates project considerable cumulative earnings of 2.982M CAD for the next 10 years with an 85% average margin. They have a unique opportunity to leverage the well documented and discussed benefits of Cannabidiol for three different cardiovascular disease markets, each in dire need of effective treatment. We believe the company to be an early takeover target in case of positive results of their COVID-19 Phase II/III trials. Price target: 15,77 CAD, Rating: BUY Die vollständige Analyse können Sie hier downloaden: Kontakt für Rückfragen GBC AG Halderstraße 27 86150 Augsburg 0821 / 241133 0 +++++++++++++++ Offenlegung möglicher Interessenskonflikte nach § 85 WpHG und Art. 20 MAR. Beim oben analysierten Unternehmen ist folgender möglicher Interessenkonflikt gegeben: (5a,5b,6a,6b,7,11); Einen Katalog möglicher Interessenkonflikte finden Sie unter: +++++++++++++++ Date (time) of completion of English version: 23/06/2021 (01:30 pm) Date (time) of first distribution of English version: 23/06/2021 (03:00 pm) -------------------übermittelt durch die EQS Group AG.------------------- Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw. Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting